Compare Citius Pharmaceuticals Inc (CTXR) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.87. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | JNK | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $98.19 |
52-Week Low | $0.48 | $94.66 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
JNK trades at $95.875, up 0.24% with a bearish technical signal from moving averages. Dividend payments of $0.52-$0.53 are scheduled through August 2026. Recent news highlights risks from AI-related corporate debt and rising oil prices affecting bond yields.
The outlook is cautious due to credit market risks and inflation concerns. Opportunities exist for income-focused investors from dividends, but volatility from Fed policy and geopolitical tensions poses significant downside risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
